These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16247455)

  • 1. The JAK2 V617F mutation in de novo acute myelogenous leukemias.
    Lee JW; Kim YG; Soung YH; Han KJ; Kim SY; Rhim HS; Min WS; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Oncogene; 2006 Mar; 25(9):1434-6. PubMed ID: 16247455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
    Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
    J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias.
    Yoo NJ; Park SW; Lee SH
    Pathology; 2012 Jan; 44(1):29-32. PubMed ID: 22081132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
    Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.
    Stevenson WS; Hoyt R; Bell A; Guipponi M; Juneja S; Grigg AP; Curtis DJ; Scott HS; Szer J; Alexander WS; Tuckfield A; Roberts AW
    Pathology; 2006 Aug; 38(4):336-42. PubMed ID: 16916724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Lee JY; Yoo NJ; Lee SH
    Leuk Lymphoma; 2006 Feb; 47(2):313-4. PubMed ID: 16321863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic mutation of IL7R exon 6 in acute leukemias and solid cancers.
    Kim MS; Chung NG; Kim MS; Yoo NJ; Lee SH
    Hum Pathol; 2013 Apr; 44(4):551-5. PubMed ID: 23069254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
    Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
    Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.